Goldman Sachs initiated coverage of 89bio (ETNB) with a Neutral rating and $11 price target 89bio is a late-stage clinical company focused on liver and cardiometabolic diseases, the analyst tells investors in a research note. While positive into the upcoming data reads on the back of “compelling” Phase 2 data and mechanistic rationale, the firm is on the sidelines ahead of the Phase 3 ENLIGHTEN-Fibrosis data in F2/F3 f non-alcoholic steatohepatitis where it believes greater clarity on pegozafermin’s clinical profile is needed.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB: